KCT0005339已完成未知
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GEN-001 in healthy male volunteers
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 50?(Year)（—）
- 性别
- Male
入选标准
- •(1) A healthy adult who is 19 ~50 years old at the screening test
- •(2) Body mass index (BMI) greater than 18.0 kg / m^2 and less than 28.0 kg / m^2 and body weight greater than 55 kg
- •? Body Mass Index (BMI) = body weight (kg) / height (m)^2
- •(3) A person who have no congenital or chronic disease within the last 3 years and have no pathological symptoms or findings as a result of medical examination
- •(4) A person who has bowel movements of Bristol Stool form scale Type 3-5 more than 3 times a week
- •(5) A person who has been judged to be suitable for the test subject to be tested at screening such as laboratory tests (hematology test, blood chemistry test, urine test, etc.) and electrocardiogram test conducted according to the characteristics of medicines
- •(6) A person who signed the written consent to participate in this study with full understanding of the purpose and contents of the examination prior to taking the test
- •(7) A persion who has the ability and willingness to participate in the study
排除标准
- •(1) A person with evidence or evidence of clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic disease (except for asymptomatic seasonal allergies at the time of administration)
- •(2) A person with a history of gastrointestinal disorders (esophageal ataxia or esophageal strictures, Crohn's disease) or surgery (except for simple cecal surgery or hernia surgery) that can affect the absorption of drugs
- •(3) Patients with a history of hypersensitivity to the drug and additives of probiotics or lactic acid bacteria preparetations or other drug(aspirin, antibiotics, etc) and food containing components
- •(4) Patients with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder
- •(5) Screening If you have a regular alcohol intake history of more than 210 g/week within 6 months (10 g of beer (5%) = 10 g, 1 glass of soju (20%) = 8 g , Wine (12%), 1 cup (125 mL) = 12 g)
- •(6) Smokers within 3 months of screening
- •(7) A persion who took other clinical trials or bioequivalence testing drugs within 6 months before the first administration of investigational product
- •(8) Anyone with a history of major alcohol or drug abuse within a year of screening
- •(9) A person who is at risk of serious adverse/chronic medical, mental, or laboratory examinations that may increase the risk due to the administration of medicines for clinical trials and participation in testing, or may interfere with the interpretation of test results
- •(10) A person who is being treated with steroid drugs
- •(11) A person who took antibiotics within 3 months of the first administration of investigational product
- •(12) A person who took a proton pump inhibitor (PPI) within 1 month prior to the first administration of investigational product
- •(13) A person who took prebiotics or probiotics within 1 month prior to the first administration of investigational product (including yogurt products)
- •(14) A person who took immunosuppressants
- •(15) A person who have unusual eating habits (e.g. grapefruit juice of 1 L or more per day) or are unable to eat the diet provided in this study
- •(16) A person who is not willing or able to comply with the guidelines for administering the subjects described in this study protocol
- •(17) Anyone deemed to be unfit for participation in this examination, as determined by the tester
研究者
相似试验
已完成
不适用
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of OMS1029 with single-dose intravenous and subcutaneous administration in healthy subjectsNL-OMON53550Omeros Corporation48
已完成
1 期
ART-001 Phase 1 studyHealthy volunteersJPRN-jRCT2080225277ARTham Therapeutics Inc.32
已完成
1 期
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648/TAK-648 in healthy Japanese volunteersHealthy volunteersJPRN-UMIN000034454Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine44
已完成
1 期
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisBronchiectasisACTRN12614001199606TB4 Sweden AB30
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12617001227381Genentech, Inc.102